NutriStack
Search the library Supplements Prescriptions Interactions Goals Symptoms Methodology
← Back to NutriStack

Show your sourcesModerate evidenceReviewed May 2026

Omega-3 fatty acids reduce cardiovascular risk, the receipts.

High-dose EPA (REDUCE-IT, 4g/day icosapent ethyl) reduces cardiovascular events in high-risk statin-treated patients. Standard-dose general-population trials (VITAL) show smaller, less consistent effects.

6 of 17 matching studies surfaced. NutriStack rating: moderate evidence. Last reviewed May 26, 2026.

How we tier evidence →Browse all claim deep dives

Moderate evidence, per the methodology. Strongest 6 studies linked to PubMed.
Recommendation, contrary evidence, and dose are all on this page.

The studies·Contrary evidence·Recommendation

The studies

Strongest evidence, sourced.

Sorted by study tier (meta-analyses first, then RCTs, then reviews) and recency. Every entry links to PubMed by PMID.

At a glance

Substances
Fish Oil, Fish Oil Triple Strength
Evidence tier
Moderate evidence
Strongest studies surfaced
6 of 17 matching
One-line verdict
High-dose EPA is real medicine; over-the-counter 1g capsules in healthy adults are not.
Last verified
May 30, 2026

Top 6 studies

  1. Meta-analysis Aung T, Halsey J, Kromhout D et al., JAMA cardiology 2018 · n=77,917

    Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals PMID 29387889

    Marine omega-3 supplementation significantly associated with reduced cardiovascular events

  2. RCT Landreth H et al., Prostaglandins Leukot Essent Fatty Acids 2023

    Comparative membrane incorporation of omega-3 fish oil triglyceride preparations differing by degree of re-esterification: A sixteen-week randomized intervention trial PMID 36706088

    16-week RCT in 60 subjects compared >95% rTG and <70% rTG fish oil preparations, demonstrating higher degree of re-esterification leads to greater omega-3 membrane incorporation.

  3. RCT Nicholls SJ, Lincoff AM, Garcia M et al., JAMA 2020

    Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial PMID 33190147

  4. RCT Bhatt DL et al., N Engl J Med 2019 · n=8,179

    Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT) PMID 30415628

    In 8,179 statin-treated patients, 4g/day icosapent ethyl (pure EPA) reduced major cardiovascular events by 25% vs placebo, establishing high-dose omega-3 cardiovascular benefit.

  5. RCT Manson JE et al., N Engl J Med 2019

    Marine omega-3 fatty acids and prevention of cardiovascular disease and cancer (VITAL trial) PMID 30415637

    In 25,871 participants over 5.3 years, 1g/day omega-3 did not reduce major cardiovascular events overall but showed a significant reduction in MI and benefit in those with low fish intake.

  6. RCT Kwong RY, Heydari B, Ge Y et al., PloS one 2019

    Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction-Post-hoc analysis from the OMEGA-REMODEL randomized controlled trial PMID 31532795

Contrary evidence

What pushes back.

Caveats, null findings, and methodological limits that hold the tier where it is.

What argues against the claim

  • VITAL and STRENGTH trials were neutral on cardiovascular events in average-risk adults.
  • High-dose omega-3 increases atrial fibrillation risk in some trials.

Recommendation

What the evidence supports.

What we recommend, with caveats

2 to 4 g/day combined EPA+DHA in re-esterified triglyceride form if triglycerides are elevated or cardiovascular risk is high. Standard 1 g supplements are unlikely to move outcomes in low-risk adults.

Tier criteria are documented at /methodology/evidence-tiers. Sourcing standards at /methodology/interactions.

Stack interaction risks

Where these substances clash.

Documented pairings involving the substances behind this claim. Cautions and conflicts come first.

Pairs in the database

Open the free interaction checker at /interactions to scan a full routine.

Goal hubs

Where this claim feeds in.

Goal-based hubs that index this claim alongside related supplements and protocols.

Related goal hubs

Before you go

One claim, opened up. NutriStack does this for every claim in the database.

The full library lives at /research. Every entry follows the same shape: the verdict, the studies, the contrary evidence, the recommendation, and the primary literature.

Browse all claim deep dives →Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.